Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review | Zendy

Abi Jenkins | Zendy; Alison H. Thomson | Zendy; Nicholas M. Brown | Zendy; Yvonne Semple | Zendy; Christine Sluman | Zendy; Alasdair MacGowan | Zendy; Andrew Lovering | Zendy; Phil Wiffen | Zendy

Open Access

Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review

Author(s) -

Abi Jenkins,

Alison H. Thomson,

Nicholas M. Brown,

Yvonne Semple,

Christine Sluman,

Alasdair MacGowan,

Andrew Lovering,

Phil Wiffen

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw250

Subject(s) - medicine , ototoxicity , amikacin , therapeutic drug monitoring , dosing , adverse effect , nephrotoxicity , regimen , randomized controlled trial , clinical trial , drug , pharmacology , intensive care medicine , toxicity , chemotherapy , antibiotics , microbiology and biotechnology , cisplatin , biology

The objectives of this study were to identify the amikacin dosage regimens and drug concentrations consistent with good outcomes and to determine the drug exposures related to nephrotoxicity and ototoxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research